Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study in Subjects With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient~* ≥18 years of age at Visit 1~* Male or Eligible Female~* Diagnosis of asthma at least 12 weeks prior to Visit 1~* Disease reversibility~* Current anti-asthma therapy~* Appropriately signed and dated informed consent has been obtained~* Able to comply with all the study requirements~Exclusion Criteria:~* History of Life-Threatening Asthma~* No use of systemic corticosteroids for any indication within 8 weeks prior to Visit~* No concurrent diseases/abnormalities that would put the safety of the subject at risk through study participation~* Drug Allergy to β2 agonist or sympathomimetic drugs, or known or suspected sensitivity to lactose or magnesium stearate~* History of severe milk protein allergy~* Non-compliance with study medication and other study-related requirements~* No use of inhaled tobacco products within the past three months or historical use of 10 pack years or more~* Administration of prohibited medications and non-drug therapies and corresponding timeframes as outlined in the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C/E/A/B/D (Type: EXPERIMENTAL): GW642444 Dose 2 QD/GW642444 Dose 4 QD/placebo/GW642444 Dose 1 BD/GW642444 Dose 3 QD
- D/C/E/A/B (Type: EXPERIMENTAL): GW642444 Dose 3 QD/GW642444 Dose 2 QD/GW642444 Dose 4 QD/placebo/GW642444 Dose 1 BD
- A/B/C/D/E (Type: EXPERIMENTAL): placebo/GW642444 Dose 1 BD/GW642444 Dose 2 QD/GW642444 Dose 3 QD/GW642444 Dose 4 QD
- B/A/D/E/C (Type: EXPERIMENTAL): GW642444 Dose 1 BD/placebo/GW642444 Dose 3 QD/GW642444 Dose 4 QD/GW642444 Dose 2 QD
- E/D/B/C/A (Type: EXPERIMENTAL): GW642444 Dose 4 QD/GW642444 Dose 3 QD/GW642444 Dose 1 BD/GW642444 Dose 2 QD/placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).